AUA/Saudi Urological Association: Best of AUA 2019 Annual Meeting (2019)

November 21, 2019 to November 23, 2019

Urologists and those practicing urology need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. This course is designed to inform on the areas that are deemed most essential: Female Pelvic Medicine, Bladder Cancer, Pediatric Urology, Endourology and Urolithiasis, BPH/LUTS, Reconstruction and Trauma, and Testicular Cancer.

Target Audience

  • Urologists

Learning Objectives

At the conclusion of this course, participants will be able to:

Female Pelvic Medicine:

  1. Describe treatment options for common female urologic conditions.
  2. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).

Bladder Cancer:

  1. Explain the risk-stratified clinical framework for the management of non-metastatic muscle-invasive and non-muscle invasive urothelial bladder cancer.
  2. Identify treatment options for non-metastatic muscle-invasive bladder cancer including chemotherapy, cystectomy, urinary diversion, lymphadenectomy, and various bladder preserving options.
  3. Discuss the diagnosis of muscle-invasive bladder cancer and the use of urine markers in addition to variant histologies, resection, intravesical therapy, BCG therapy, cystectomy, enhanced cystoscopy and patient follow-up. 
  4. Integrate AUA guidelines into clinical practice.

Pediatric Urology:

  1. Diagnose, manage and provide consultation for complications such as hydronephrosis and bladder exstrophy. 
  2. Diagnose and provide cost-effective management of common pediatric urology problems including Ureterocele and Ectopic Ureter.
  3. Outline evaluation, medical and surgical management, of common postnatal obstruction of the urinary tract, including UPJ obstruction, UVJ obstruction and posterior urethral valves.

Endourology and Urolithiasis:

  1. Interpret metabolic evaluations for patients with kidney stones according to the published guidelines.
  2. Discuss the use of medications in the prevention of kidney stones, including side effects.
  3. Outline dietary considerations used for the prevention of stones.
  4. Explain the recommended preoperative evaluation for patients considering kidney stone surgery (including laboratory studies and imaging).
  5. Describe a surgical treatment plan for patients with kidney and/or ureteral stones in adult and pediatric patients, including surgical approach and discussion of complications.

BPH/LUTS:

  1. Explain the role of diagnostic testing in making the accurate diagnosis of male LUTS using the new BPH Guidelines.
  2. Identify common pathophysiological etiologies of voiding and sexual health.
  3. Define the safety and efficacy of new minimally invasive options for BPH including prostatic urethral lift and convective water vapor therapy and surgical options such as Aquablation and electrosurgical and laser therapies.
  4. Describe the impact of current therapeutic strategies on both voiding and sexual dysfunction.

Reconstruction/Trauma:

  1. Differentiate among the variety of etiologies of ureteral strictures.
  2. Describe and summarize radio-graphic testing to accurately define the stricture.
  3. Identify key steps in surgical techniques to provide for best possible surgical results.
  4. Describe guidelines-driven, evidence-based treatment algorithms for injuries to the kidney, ureter, bladder, urethra and external genitalia.
  5. Distinguish between injuries that require non-operative surveillance, immediate surgery, and adjunctive interventions such as angio-embolization or endourologic management.

Testicular Cancer:

  1. Describe treatment options for patients with clinical stages I, IIA, and IIB seminoma and nonseminomatous (NSGCT) germ cell tumors and utilize the low-stage testis cancer treatment algorithm. 

 

Course summary
Available credit: 
  • 15.75 AMA PRA Category 1 Credit™
  • 15.75 Non-Physician Participation
Course opens: 
11/21/2019
Course expires: 
11/23/2022
Event starts: 
11/21/2019 - 7:00am
Event ends: 
11/23/2019 - 5:30pm
Rating: 
0
Thursday, 21 November 2019
13:00 – 13:05SUA Welcome Remarks – Raed A. Azhar, MD, SUA President
AUA Welcome Remarks – Sam S. Chang, MD, MBA, AUA Assistant Secretary
Endourology and Urolithiasis—Session I
13:05 – 13:25Surgical Treatment of Urolithiasis: State of the Art and What's New?
Dr. Scott Cheney
13:25 – 13:45Endourology Complications: How to Avoid Them and How to Manage Them?
Dr. Scott Cheney
13:45 – 14:05Stone Prevention: Where Are We Now and Where Do We Need to Go?
Dr. Scott Cheney
14:05 – 15:00Endourology and Urolithiasis Case Presentations
Drs. Raed Azhar, Ashraf Abusamra, Ahmad Alzahrani, and Scott Cheney
15:00 – 15:30Afternoon Break
15:30 – 15:40 AUA 2019 Take Home Messages: Urolithiasis and Endourology
Dr. Scott Cheney
Pediatrics Urology | Dr. Jeffrey Donohoe
15:40 – 16:00 Urinary Tract Reconstruction in Children
16:00 – 16:20 Ureterocele and Ectopic Ureter
16:20 – 16:35 Bladder Exstrophy
16:35 – 16:50 Posterior Urethral Valves
16:50 – 17:20 Pediatric Urology Case Presentations
Drs. Raed Azhar, Ashraf Abusamra, Ahmad Alzahrani, and Dr. Jeffery
17:20 – 17:30 AUA 2019 Take Home Messages: Pediatric Urology
Friday, 22 November 2019
8:00 – 9:00Resident Breakfast with the Experts – Urolithiasis and Endourology
Dr. Scott Cheney
Female Pelvic Medicine | Dr. Alexander Gomelsky
9:00 – 9:20UDS: Unique and Key Findings
9:20 – 9:40Interstitial Cystitis: Update
9:40 – 10:10Female Pelvic Medicine Case Presentations
Drs. Raed Azhar, Ashraf Abusamra, Ahmad Alzahrani, and Alexander Gomelsky
10:10 – 10:30Treatment of Vesico-vaginal Fistula
10:30 – 10:50Treatment of Incontinence and Prolapse
10:50 – 11:10Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA/SUFU Guideline
11:10 – 11:30OAB Medications: An Update and What to Use When
11:30 – 11:40AUA 2019 Take Home Messages: Female Pelvic Medicine
11:40 – 13:30Afternoon Break
Oncology: Session 1 | Dr. Sam Chang
13:30 – 13:50Urinary Markers and Cytology: Review and Update
13:50 – 14:10Management of NMIBC: Practical Solutions for Common Problems
14:10 – 14:30Bladder Sparing Regimens: Do They Work?
14:30 – 14:45AUA 2019 Take Home Messages: Bladder Cancer
14:45 – 15:15Afternoon Coffee Break
15:15 – 16:00Tumor Board Case Presentations
Drs. Raed Azhar, Ashraf Abusamra, Ahmad Alzahrani, and Sam Chang
Endourology and Urolithiasis—Session 2
16:00 – 16:15Comparing Outcomes of ESWL vs. Ureteroscopy
Dr. Scott Cheney
16:15 – 17:10Surgical Techniques Video Panel
Tips & Tricks: Percutaneous Nephrolithotomy/Urteroscopy (PCNL/URS)
Drs. Raed Azhar, Ashraf Abusamra, Ahmad Alzahrani, and Scott Cheney
Saturday, 23 November 2019
8:00 – 9:00Resident Breakfast with the Expert—Uro–Oncology
Drs. Sam Chang and Wade Sexton
BPH/LUTS | Dr. Scott Cheney
9:00 – 9:20Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline
9:20 – 9:40Comparison of Surgical Treatment Options for BPH
9:40 – 9:50AUA 2019 Take Home Messages: BPH/LUTS
Dr. Ashraf Abusamra
Reconstruction/Trauma | Dr. Kurt McCammon
10:35 – 10:55Treatment of urethral stricture disease—Guidelines and What is Important
10:55 – 11:15Urologic Trauma: Evaluation and Treatment—Upper tract
11:15 – 11:35 Urologic Trauma: Evaluation and Treatment—Lower Tract
11:35 – 11:50Peyronie’s Disease: New Management Strategies
11:50 – 13:00Afternoon Break
13:00 – 13:25Transitional Urology: Adult Manifestations of pediatric conditions or The Adult Care of the pediatric patient
13:25 – 13:40AUA 2019 Take Home Messages: Urologic Reconstruction & Trauma
Oncology: Session 2 | Dr. Wade Sexton, Dr. Sam Chang and Dr. Raed Azhar
13:40 – 14:00AUA Guideline: Diagnosis and Treatment of Early Stage Testicular Cancer
14:00 – 14:20Treatment for Late Relapse and Salvage Therapies
14:20 – 14:45Screening and Epidemiology Changes: Is Testis Cancer Becoming More Common?
14:45 – 15:15Afternoon Coffee Break
15:15 – 15:35Upper Tract Urothelial Carcinoma: Neoadjuvant or Adjuvant Chemotherapy
15:35 – 15:55Robotic Surgery for Upper Tract Cancer
15:55 – 16:05Penile, Testis, and Urethral Cancer Take Home Message
16:05 – 16:25The Role of the Urologist in Metastatic Prostate Cancer
16:25 – 16:40AUA 2019 Take Home Messages—Prostate and Kidney Cancer
16:40 – 17:00What Can AUA Do For You and AUA/SUA Collaborations
Dr. Sam Chang and Dr. Raed Azhar
17:00 – 17:10Closing Remarks/Adjourn
Dr. Raed A. Azhar, SUA President
Riyadh Marriott Hotel
Riyadh, The Kingdeom of Saudi Arabia
Saudi Arabia

Faculty Disclosures

 

Name

Company

Role

Financial

 

Ashraf J. Abusamra, MD

Nothing to disclose

Ahmed Alzahrani

Nothing to disclose

Raed Azhar, MD

Nothing to disclose 

Sam Chang, MD

Astellas

Consultant or Advisor

Yes

 

NIH

  Scientific Study or Trial

  Yes

 

GLG

Consultant or Advisor

Yes

 

Janssen

Consultant or Advisor

Yes

 

Want

Consultant or Advisor

Yes

 

BMS

Consultant or Advisor

Yes

 

Pfizer

Consultant or Advisor

Yes

 

Urovant

Consultant or Advisor

Yes

 

UroGen

Consultant or Advisor

Yes

 

UroToday

Consultant or Advisor

Yes

 

Scott Cheney, MD

Nothing to disclose

 

Jeffrey  Donohoe, MD

Nothing to disclose

Alexander Gomelsky, MD

Cook Myosite

Scientific Study or Trial

Kurt McCammon, MD

Urology Of Virginia

Leadership Position, Employee

Yes

Boston Scientific

Consultant or Advisor, Meeting Participant or Lecturer

Yes

Allergan

Health Publishing, Scientific Study or Trial

No

Solace

Scientific Study or Trial

Yes

IVUmed

Leadership Position

Yes

Cook

Scientific Study or Trial

Yes

Wade Sexton, MD

Nothing to disclose

 

Education Council Disclosures

PDF iconEducation Council Disclosures

AUA Office of Education Staff have nothing to disclose. 

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 15.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


 

Available Credit

  • 15.75 AMA PRA Category 1 Credit™
  • 15.75 Non-Physician Participation
Please login or register to take this course.

AUA Participant Information and Policies


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.